ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of ...
(WorldNews Health)

BURLINGTON, Mass.--(BUSINESS WIRE)--$ARQL #ARQ531--ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid, Spain. ARQ 531 is an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton´s tyrosine kinase (BTK). The presentation titled `ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in ABC-DL ......